Background: Numerous clinical infections, from mucocutaneous infections to potentially fatal invasive illnesses, are caused by Candida species, and the rise in antifungal medication resistance has raised severe concerns. Over the last ten years, antifungal agent resistance has grown. Therefore, testing for antifungal susceptibility and identifying Candida up to the species level are crucial for managing Candida infections. The study's objectives were to distinguish between different species of Candida and ascertain how susceptible each species was to antifungal medications. Materials and methods: The investigation comprised 120 consecutive, non-repetitive Candida isolates from a variety of clinical specimens, including high vaginal swabs, urine, sputum, pus, catheter tips, ear swabs, and stool samples from patients with antibiotic-associated diarrhoea. Direct samples were used to do Gram's stain, which was then inoculated into Sabouraud dextrose agar and incubated for 24 hours at 37°C. The investigation excluded isolates that were identified as fungi other than Candida species. To identify Candida species, a colony on Sabouraud dextrose agar was treated. The isolates underwent urea hydrolysis testing, germ tube testing, Gram's staining, and macroscopic inspection. Result: A total of 90 Candida spp. was isolated from various clinical samples. Distribution of samples of Candida isolates were mentioned in Table 2. Candida albicans (49.5%) was the most common species isolated. Conclusion: Finding the species that are inherently resistant is aided by the species-level characterisation of Candida. Non-albicans Candida species, such as Candida tropicalis, Candida krusei, Candida glabarata, and Candida dubliniensis, are also increasingly being identified from clinical specimens in addition to Candida albicans. For identifying such species, CHROM agar is an easy, quick, and affordable technique with excellent sensitivity and specificity.